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Purpose: Combined hepatocellular-cholangiocarcinoma (CHCC) is an uncommon 
form of cancer, and its clinicopathological features have rarely been reported in de-
tail. This study was undertaken to evaluate the clinicopathological characteristics and 
prognostic factors of CHCC. Materials and Methods: The clinicopathological fea-
tures of patients diagnosed with CHCC at Severance Hospital between January 1996 
and December 2007 were retrospectively studied by comparing them with the fea-
tures of patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) 
who had undergone a hepatic resection during the same period. Results: Forty-three 
patients diagnosed with CHCC were included in this study (M : F=35 : 8, median 
age, 55 years). According to the parameters of the American Joint Committee on 
Cancer staging, there were 6 (14.0%), 9 (20.9%), 25 (58.1%), and 3 (7.0%) patients 
with stages I, II, III, and IV cancer, respectively. Thirty-two of the 43 patients under-
went resection with curative intent. After resection, 27 patients (84.4%) had tumor 
recurrence during the follow-up period of 18 months (range: 6-106 months), and the 
median time to recurrence was 13 months. Overall median survival periods after he-
patic resection of CHCC, HCC and CC were 34, 103 and 38.9 months, respectively 
(p<0.001). The median overall survival for all patients with CHCC was 21 months, 
and the 5-year survival rate was 18.1%. The presence of portal vein thrombosis and 
distant metastasis were independent prognostic factors of poor survival. Conclusion: 
Even after curative hepatic resection, the presence of a cholangiocellular component 
appeared to be a poor prognostic indicator in patients with primary liver cancer.
Key Words:   Combined hepatocellular and cholangiocarcinoma, hepatocellular 
carcinoma, cholangiocarcinoma
INTRODUCTION
Primary liver cancer is a major worldwide health problem. Most primary cancers of 
the liver are classified into two major types: hepatocellular carcinoma (HCC), which 
originates in the hepatocytes, and cholangiocarcinoma (CC), which originates from 
the epithelial cells in the bile duct. However, a small proportion of tumors, namely 
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about all the patients. The parameters reviewed included gen-
der, age, clinical presentation, alcohol consumption, viral 
hepatitis B and C status, patterns of contrast-enhanced dy-
namic CT (HCC-like pattern, CC-like pattern, and mixed 
pattern), laboratory data [serum aspartate aminotransferase 
(AST), serum alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), gamma-glutamyl transferase (GGT), to-
tal bilirubin, albumin, and prothrombin time (PT)]. Each CT 
was read by two radiologists who had no information about 
the pathological results. An HCC-like pattern was defined as 
high attenuation/signal intensity in the early phase and low 
attenuation/signal intensity in the delayed phase. A CC-like 
pattern was defined as low attenuation/signal intensity in the 
early phase, and iso- or high attenuation/signal intensity in 
the delayed phase. A mixed pattern was defined as a mix of 
both of these patterns.9,10 To evaluate the degree of hepatic 
disease, the Child-Pugh status was defined in each patient.
In all of the selected patients, we obtained histopatholog-
ic information regarding the size, number, and location of 
tumor(s), presence of capsule, portal vein thrombosis, lymph 
node metastasis, intrahepatic metastasis, and distant metas-
tasis. Tumor staging was performed in accordance with the 
American Joint Committee on Cancer (AJCC) staging sys-
tem, 6th edition. The surgical method was categorized as 
limited resection, in which the segment containing the tumor 
was resected; a major hepatic resection, in which more than a 
single segment was resected; and liver transplantation.
With respect to survival outcomes, we analyzed median 
survival time, 1-year, 3-year, and 5-year survival rates, medi-
an disease-free survival, cumulative recurrence rates, and re-
currence sites. The prognostic factors analyzed were age, sex, 
presence of cirrhosis, hepatic function (Child-Pugh class), 
positive serum viral marker, tumor size, number of tumors, 
patterns of CT, presence of capsule, portal vein thrombosis, 
lymph node metastasis, distant metastasis, and AJCC stage.
Statistical analysis
Statistical analysis was performed using the Statistical Pack-
age for Social Sciences (SPSS version 16.0). Data values are 
reported as the median (range) or as n (%). Student’s t-tests 
and χ2-tests were used for statistical analysis. Univariate 
analysis was performed to identify predictors of survival 
using the Kaplan-Meier method, and survival curves were 
compared using the log-rank test. The results of the univari-
ate analysis were considered significant if the probability of 
occurrence by chance was 5% or less (p<0.05). For contin-
uous variables, the cutoff was set at the median value. Mul-
combined hepatocellular-cholangiocarcinoma (CHCC), 
show a mixture of hepatocellular and glandular features.1-3 
According to the World Health Organization classification, 
this condition, defined as a tumor containing components of 
both HCC and CC,4 is a very rare form of primary liver can-
cer in which dual differentiation toward hepatocytes and bile 
duct epithelia coexist.5 Since Allen and Lisa first described 
the features of this tumor in 1949,6 few reports have exam-
ined its clinical features, survival outcomes, or prognostic 
factors. Many reports have increasingly raised concerns re-
garding CHCC. Because of its low prevalence, however, lit-
tle is known about the clinicopathological characteristics and 
prognoses of patients with CHCC, and comparing the out-
come of patients with CHCC to that of patients with HCC or 
CC has yielded conflicting results in a few studies. Some in-
vestigators have suggested that the biological features of 
CHCC resemble those of HCC rather than those of CC,7 and 
that the prognosis for patients with CHCC is worse than for 
pure HCC and better than for pure CC.1,2 In contrast, Jarnag-
in, et al.8 reported that the clinical features of CHCC were 
more similar to those of CC, and that the 5-year survival rate 
of patients with CHCC was lower than that of patients with 
either HCC or CC. To fully clarify the characteristics, surviv-
al, and prognostic factors of CHCC, we retrospectively ana-
lyzed the clinicopathological characteristics and prognostic 
factors related to survival and recurrence in patients diag-
nosed with CHCC at a single center. We also compared pa-
tients with CHCC to those with HCC or CC who had under-
gone an operation during the same study period.
MATERIALS AND METHODS
　　　
Patients
We studied 43 patients who were diagnosed with CHCC, as 
confirmed by pathologic findings, at Severance Hospital 
between January 1996 and December 2007. Pathological 
specimens were obtained via needle biopsy in 11 patients 
and hepatectomy in 32. The median follow-up period was 
18 months (range: 6-106 months). The data records of 368 
patients with ordinary HCC and 128 patients with CC who 
had undergone an operation during the same period were 
selected and reviewed for comparison. This study was ap-
proved by the local institutional review board. 
Methods
A retrospective review of a database provided information 
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tivariate analysis was performed using Cox proportional 
hazards regression analysis. 
RESULTS
 　
CHCC clinical and pathological characteristics 
The baseline characteristics of 43 patients with CHCC are 
provided in Table 1. The median age was 55 years (range: 
30-72 years); there were 35 men (81.4%) and eight women 
(18.6%). The prevalence of the hepatitis B surface antigen 
was 62.8%, and positive serology for hepatitis C infection 
was found in 14.0% of patients. Underlying liver cirrhosis 
was found in 29 (67.4%) patients. If we assumed that all the 
patients had liver cirrhosis, 31 (72.1%) were classified as 
Child-Pugh class A, and 12 (27.9%) were in Child-Pugh 
class B. Regarding patterns of contrast-enhanced dynamic 
CT, 28 patients exhibited an HCC-like pattern, 12 exhibited 
a CC-like pattern, and three exhibited a mixed pattern.
According to the AJCC staging classification, 6 patients 
(14.0%) were in stage I, 9 (20.9%) in stage II, 25 (58.1%) in 
stage III, and three (7.0%) in stage IV. Thirty-two patients 
(74.4%) were pathologically diagnosed by operation and 11 
patients (25.6%) by gun-biopsy. Nine patients (21.0%) un-
derwent medical treatment; systemic chemotherapy (one 
patient), intra-arterial chemotherapy (four patients), and tran-
sarterial chemo-embolization (four patients). One patient un-
derwent radiotherapy, and another refused treatment. Among 
five patients who had treated systemic or intra-arterial che-
motherapy, most of them (four) had received a platinum 
complex-based regimen (systemic/intra-arterial cisplatin or 
intra-arterial carboplatin). One patient received combina-
tion chemotherapy with systemic 5-fluorouacil and cisplat-
in. The other received combination chemotherapy of sys-
temic adriamycin and mitomycin.
CHCC: Survival and recurrence
Thirty-two patients (74.4%) died during the follow-up peri-
od, and the median overall survival was 21 months (range: 
6-106 months). The 1-year overall survival rate was 69.0%, 
the 3-year overall survival rate 34.1%, and the 5-year over-
all survival rate was 18.1% (Fig. 1).
Univariate analysis identified the predictive factors of over-
all survival as absence of cirrhosis, negative serum viral mark-
er, presence of capsule formation, portal vein thrombosis, dis-
tant metastasis and advanced AJCC stage. In the stepwise 
Cox multivariate regression analysis, the presence of portal 
Table 1. Baseline Characteristics of Patients with CHCC (n=43)
Characteristics CHCC (n=43)
Age (yrs)     55 (30-72)
Gender
    Male      35 (81.4)
    Female        8 (18.6)
Viral infection
    HBs Ag (+)      27 (62.8)
    HCV Ab (+)        6 (14.0)
Cirrhosis      29 (67.4)
Child-Pugh class A*/B      31 (72.1)/12 (27.9)
Laboratory lab
    AST (IU/L)   88.8 (12-522)
    ALT (IU/L)   88.5 (12-313)
    ALP (IU/mL) 155.7 (48-691)
    Gamma-GT (mg/dL) 141.9 (14-603)
    T.bilirubin (mg/dL)     3.1 (0.3-39.5)
    Albumin (g/dL)     3.6 (2.4-4.6)
    AFP (ng/mL) 316.4 (2.0-4,107.0)
Pattern of CT
    HCC-like      28 (65.1)
    CC-like      12 (27.9)
    Mixed        3 (7.0)
Tumor size
    <5 cm      24 (55.8)
    ≥5 cm      17 (39.5)
    Diffuse        2 (4.7)
Tumor location
    Left lobe        8 (18.6)
    Right lobe      28 (65.1)
    Both lobe        7 (16.3)
Tumor number
    Solitary      28 (65.1)
    Multiple      15 (34.9)
Capsule formation      17 (39.5)
Portal vein thrombosis      18 (41.9)
Lymph node metastasis        7 (16.3)
Intrahepatic metastasis      12 (27.9)
Distant metastasis        3 (7.0)
Stage (AJCC 6th)†
    I        6 (14.0)
    II        9 (20.9)
    III      25 (58.1)
    IV        3 (7.0)
CHCC, combined hepatocellular-cholangiocarcinoma; HBsAg, hepatitis B 
virus surface antigen; HCV Ab, hepatitis C virus antibody; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phospha-
tase; Gamma-GT, gamma-glutamyl transferase; AFP, alpha-fetoprotein; 
CC, cholangiocarcinoma. 
Results are expressed as median (range) or n (%).
*Child-Pugh A includes non-cirrhotic hepatitis.
†AJCC 6th, American Joint Committee on Cancer staging system, 6th edi-
tion.
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only supportive care after detection of recurrence. In the uni-
variate analysis, predictive factors of recurrence were the 
presence of lymph node metastasis and distant metastasis 
(p=0.016 and <0.001, respectively). Although the presence 
of distant metastasis was still significant [relative risk 21.685 
(95% CI, 2.698-67.394)] in the multivariate analysis as ex-
pected, the relative risk of the presence of lymph node me-
tastasis was not significant (p=0.690) (data not shown).
CHCC vs. HCC or CC; Comparison of 
clinicopathological characteristics & clinical outcomes
To compare outcomes after hepatic resection, 32 patients who 
had been diagnosed by surgical operation were compared 
with 368 HCC patients and 128 CC patients who had been di-
agnosed by pre-operative evaluation studies (imaging modali-
ties and tumor markers) and had undergone an operation dur-
ing the same period. The clinical features of the three patient 
groups are summarized in Table 3. Significant differences 
were observed in the status of viral infection, the presence of 
cirrhosis, Child-Pugh status, AST, ALT, and albumin level of 
the three groups. Positive serum HBs Ag was most frequently 
showed in patients with HCC (81.2% vs. 68.8%, 7.8%, 
p<0.001), and positive anti-HCV Ab was relatively more fre-
quent in patients with CHCC (15.6% vs. 6.8%, 1.6%, 
p=0.007). The prevalence of cirrhosis in patients with CHCC 
(75.0%) was high compared to patients with HCC (53.5%) 
and CC (15.6%) (p=0.025). Child-Pugh class A was more fre-
quently found in the HCC group than in the CHCC and CC 
groups (p=0.006). Levels of AST and ALT were significantly 
higher in the CHCC group (p=0.047, 0.037, respectively), and 
the level of albumin in the CHCC group was lower than in the 
other two groups (p=0.029). Even though the difference was 
vein thrombosis and distant metastasis had an independent ef-
fect on overall survival (Table 2). The multivariate relative 
risk for the presence as compared to the absence of portal vein 
thrombosis was 2.745 [95% confidence interval (CI), 1.192-
6.232, p=0.018], and the risk for the presence of distant me-
tastasis was 21.685 (95% CI, 3.276-143.555, p=0.001).
Twenty-seven of 32 patients who had undergone curative 
resection (84.4%) had recurrence during the follow-up peri-
od, and the median disease-free survival was 13 months 
(range, 2-41 months). Among 27 patients with recurrent 
CHCC, intrahepatic metastases were detected in 13 patients 
(40.6%), and extrahepatic metastases were detected in 14 
(43.8%). After recurrence, 27 patients underwent further 
treatment, including reoperation (eight patients), systemic 
chemotherapy (seven patients), trans-arterial chemo-embo-
lization (three patients), intra-arterial chemotherapy (one 
patient), and radiotherapy (one patient). Seven patients had 
Fig. 1. Kaplan-Meier overall survival rate of combined hepatocellular-chol-
angiocarcinoma (CHCC) (n=43).
Table 2. Factors Prognostic of Overall Survival in CHCC (n=43)
Variable
Univariate analysis,  
p value
Multivariate analysis,  
p value
Hazard ratio  
(95% CI)
Age (≥60 vs. <60) 0.856
Gender (M vs. F) 0.978
Liver cirrhosis (presence vs. absence) 0.035 0.175
Child-Pugh (A vs. B) 0.833
Serum viral marker (presence vs. absence) 0.040 0.395
Multiple vs. Solarity 0.727
Tumor size (≥5 cm vs. <5 cm) 0.064
Capsule formation (presence vs. absence) 0.026 0.084
Portal vein thrombosis (presence vs. absence) 0.002 0.018 2.745 (1.192-6.232)
Lymph node metastasis (presence vs. absence) 0.288
Distant metastasis (presence vs. absence) <0.001 0.001   21.685 (3.276-143.555)
Stage (III/IV vs. I/II) 0.041 0.105
CHCC, combined hepatocellular-cholangiocarcinoma
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served liver functions at the time of operation.
Surgical methods and pathological characteristics for the 
three groups are provided in Table 4. Tumor size and location 
not significant, the total bilirubin levels were slightly higher in 
the CHCC group than in the other two groups (p=0.070). All 
these results show that patients with CHCC had badly pre-
Table 3. Clinical Characteristics of Patients with CHCC (n=32), HCC (n=368) and CC (n=128)
Characteristics CHCC (n=32)  HCC (n=368)     CC (n=128) p value
Age (yrs)    55 (40-72)     53 (24-76)     61 (44-85) 0.139
Gender 0.100
Male 26 (81.2) 279 (75.8)   86 (67.2)
Female   6 (18.8)   89 (24.2)   42 (32.8)
Viral infection
HBs Ag (+) 22 (68.8) 299 (81.2) 10 (7.8) <0.001
HCV Ab (+)   5 (15.6) 25 (6.8)   2 (1.6) 0.007
Cirrhosis 24 (75.0) 197 (53.5)   20 (15.6) <0.001
Child-Pugh class A*/B 24 (75.0)/8 (25.0) 362 (98.4)/6 (1.6) 122 (95.3)/6 (4.7) 0.006
Laboratory lab
    AST (IU/L)      52 (12-522)       33 (11-266)        25 (12-433) 0.047
    ALT (IU/L)      51 (12-313)     34 (3-417)      22 (7-316) 0.037
    ALP (IU/mL)    101 (48-301)       91 (19-539)      110 (11-744) 0.054
    Gamma-GT (mg/dL)      72 (14-385)       53 (10-954)        89 (11-633) 0.058
    T.bilirubin (mg/dL)       0.9 (0.3-28.8)      0.6 (0.1-8.1)       0.6 (0.2-6.3) 0.070
    Albumin (g/dL)     3.7 (2.5-4.6)      4.1 (2.2-5.0)       4.0 (3.0-5.0) 0.029
    AFP >200 (ng/mL)    7 (21.9)   55 (14.9) 0 (0) <0.001
CHCC, combined hepatocellular-cholangiocarcinoma; HCC, hepatocellular-carcinoma.
Results are expressed as median (range) or n (%).
*Child-Pugh Class A includes non-cirrhotic hepatitis.
Table 4. Surgical Methods and Pathological Characteristics for Patients with CHCC (n=32), HCC (n=368) and 
CC (n=128)
Characteristics CHCC (n=32) HCC (n=368) CC (n=128) p value
Surgical method 0.005
    Limited resection 10 (31.2) 196 (54.0)   32 (25.0)
    Major resection 21 (65.6) 167 (46.0)   96 (75.0)
    Liver transplantation 1 (3.1)   0 (0) 0 (0)
Tumor size 0.083
    <5 cm 19 (59.4) 225 (61.1)   56 (43.8)
    ≥5 cm 13 (40.6) 143 (38.9)   72 (56.2)
Tumor location 0.053
    Left lobe   5 (15.6)   94 (25.7)   58 (45.3)
    Right lobe 23 (71.9) 232 (63.4)   52 (40.6)
    Both lobe   4 (12.5)   40 (10.9)   18 (14.1)
Tumor number <0.001
    Solitary 21 (65.6) 318 (86.9) 122 (95.3)
    Multiple 11 (34.4)   48 (13.1)   6 (4.7)
Capsule formation 14 (43.8) 245 (75.4)   32 (25.0) <0.001
Portal vein thrombosis 12 (37.5) 21 (5.8)   74 (57.8) <0.001
Lymph node metastasis   4 (12.5) 25 (6.8)   34 (26.6) <0.001
Intrahepatic metastasis 10 (31.2)   54 (14.9)   14 (10.9) 0.015
Stage (AJCC 6th) 0.036
    I/II 12 (37.6) 343 (93.2)   82 (64.1)
    III/IV 20 (62.4) 25 (6.8)   46 (35.9)
CHCC, combined hepatocellular-cholangiocarcinoma; HCC, hepatocellular-carcinoma; CC, cholangiocarcinoma; AJCC 6th, american 
Joint Committee on Cancer 6th.
Results are expressed as n (%).
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tically significant (p=0.562).
DISCUSSION
   
Since the first comprehensive description about primary liver 
cancer comprising elements of HCC and CC was published 
in 1949,6 several studies have been performed regarding the 
clinicopathological features of CHCC. Because CHCC is en-
countered infrequently, useful clinical data is limited. More-
over, only a few reports give information about surgical treat-
ment and clinical outcomes after hepatic resection.
The incidence of CHCC varies considerably, from 2.4% 
reported by Goodman, et al.11 to 14.2% from the data series 
of Allen and Lisa.6 Liu, et al.12 reported an incidence of 
2.0%, and the Liver Cancer Study Group of Japan showed 
that the CHCC group accounted for 1.2% of surgical cases 
and 1.6% of autopsy cases.7 To estimate the incidence in 
our study, we included only patients who had liver cancer 
and underwent hepatic resection, because CHCC could be 
missed or misdiagnosed as HCC in patients who underwent 
biopsy only. Thus, among the 972 patients who underwent 
hepatic resection for primary liver cancer in our institution, 
32 were found to have CHCC, an incidence rate of 3.3%.
The cellular origin of CHCC cells remains unclear. Three 
possibilities have been proposed for their histogenesis: 1) 
the cells represent double cancer with dual differentiation 
of hepatocytes and bile duct epithelium; 2) the cancer initial-
ly developed from either hepatocytes or bile duct epithelium 
and differentiated from other components; or 3) the cancer 
developed in intermediate cells that subsequently differenti-
ated into CHCC.12 
Histologic diagnosis of CHCC depends on the demon-
stration of dual differentiation of hepatocellular and biliary 
epithelial features, with distinct immunohistochemical fea-
tures demonstrating malignant transformation in both he-
patic and biliary cells.13,14 Radiologically, Lin G, et al.15 re-
ported that the imaging pattern for CHCC can be an HCC-
like pattern, a CC-like pattern, or a mixed pattern. On the 
other hand, some authors have suggested that a target-like 
appearance on the sonography, presented as a hypovascular 
mass with central hypervascular portions on angiography, 
revealed an enhancing pattern around or within the mass on 
the enhanced CT that may be helpful in making an accurate 
radiologic diagnosis of CHCC.16,17 However, the diagnostic 
criteria for CHCC remain controversial because clinical ex-
perience with patients with CHCC from a single center is 
were similar between the three groups (p=0.085, p=0.053, re-
spectively). Differences in the number of tumors, the pres-
ence of capsules, portal vein thrombosis, and the frequency 
of advanced staged tumors were observed between the three 
groups. Multifocal disease was seen more frequently in the 
CHCC group than in the other two groups (p<0.001). The 
CHCC group had intermediate prevalence of capsule for-
mation and portal vein thrombosis compared to the HCC 
group and CC group (43.8% vs. 75.4% vs. 25.0%, 37.5% vs. 
5.8% vs. 57.8%, p<0.001 for both). Lymph node metastasis 
in CHCC occurred with a similar frequency as in CC (12.5% 
vs. 26.6%, p=0.095), and significantly more frequently than 
in HCC (12.5% vs. 6.8%, p<0.001). The frequency of intra-
hepatic metastasis and the proportion of advanced tumor 
stage in the CHCC group were higher than in the HCC group 
and the CC group (p=0.015, 0.036, respectively).
After resection for combined tumors, the one-year sur-
vival rate was 79.7%; the three-year survival rate 45.0%; 
and the five-year survival rate was 23.8%. All of these were 
lower than those of the HCC group (91.9%, 74.8%, and 
69.1%, respectively), and comparable with those of the CC 
group (76.6%, 52.7% and 39.5%, respectively) (Fig. 2). The 
median survival time for the CHCC group (34 months) was 
significantly shorter than for the HCC and CC groups (103 
and 38.9 months, respectively; p<0.001). 
Twenty-seven patients (84.4%) in the CHCC group had a 
recurrence during the follow-up period, which was a recur-
rence rate much higher than that of HCC (52.7%) or CC 
(64.1%) (p<0.001). The median disease-free survival was 
13 months with CHCC, 10 months with HCC group and 
12.3 months with CC, and these differences were not statis-
Fig. 2. Kaplan-Meier overall survival rate of combined hepatocellular-chol-
angiocarcinoma (CHCC) (n=32), HCC (n=368) and CC (n=128). HCC, hepato-
cellular-carcinoma; CC, cholangiocarcinoma.
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contrast, the comparison of prognosis between CHCC and 
CC is still controversial.1,2,14 Our study demonstrated that 
patients with CHCC tended to have poorer survival out-
comes than those with either HCC or CC. Okuda20 reported 
that patient prognosis with CHCC was poorer than for HCC 
because lymph node metastasis occurs more frequently. For 
this reason, our results showing more frequent lymph node 
metastasis in CHCC than in HCC might explain the poorer 
survival outcomes for CHCC than for HCC. In addition, 
several characteristics of CHCC ascertained above might 
contribute to poor survival outcome: poorly preserved liver 
function, more frequent multiplicity and more frequent in-
trahepatic metastasis. 
Meanwhile, in the comparison of survival outcomes based 
on tumor stages, no significant differences were observed 
between the two groups, especially in the earlier tumor stag-
es. This result suggests that a poor survival outcome of 
CHCC might be attributed mainly to more advanced tumor 
status at the time of surgery. Vulnerability to multiplicity, 
intrahepatic metastasis and lymph node metastasis of CHCC 
would be reasons for more advanced tumor status, and 
these findings collectively suggested unfavorable tumor bi-
ology of CHCC.7 This unfavorable behavior of CHCC may 
be connected with tumor cells originating from pleuripotent 
hepatic precursor cells.21,22 Therefore, further study will be 
necessary to elucidate the features of tumor cells in CHCC. 
Also, based on the comprehension of characteristic behav-
iors of CHCC, a proper preoperative work-up and early di-
agnosis of CHCC would certainly be important to improve 
its survival rate.
We recognize several limitations in our study. This study 
was retrospective and could have been affected by any and 
all of the limitations of this investigational design. The pos-
sibility of selection bias is another potential limitation of this 
study. Moreover, the comparison of the CHCC, HCC and 
CC groups with different tumor characteristics and stages 
had an inherent bias that made our conclusions of poor val-
ue regarding tumor recurrence and survival rates. This was 
because many cases that were considered to be operable 
were later found in the operating room to be more progressed 
than they had appeared in the pre-operative studies. There-
fore, precise preoperative evaluation will be necessary to 
improve clinical outcomes for patients with CHCC. Like 
most other reports on CHCC, our study had a small number 
of patients, because the data were taken from a single cen-
ter, which might have hampered the identification of possi-
ble important predictive factors. Because the incidence of 
very limited. Moreover, the clinical characteristics of CHCC 
are inconsistent due to discrepancies in the diagnostic crite-
ria and clinical populations in published studies. In our stud-
ies, most of the CHCC patients (65.1%) showed an HCC-
like pattern in the pre-operative enhanced CT. Without 
histological evidence, these patients may have been misdi-
agnosed with HCC. Therefore, it is very difficult for pa-
tients with CHCC to be correctly diagnosed before under-
going an operation. Because diagnosis is difficult during 
the pre-operative period, the true incidence is likely to be 
much higher than what has been reported, our series includ-
ed. Because CHCC has characteristics of both portal vein 
invasion of HCC and lymph node metastasis of CC, patients 
with CHCC were in a more advanced stage of the disease 
than were those with HCC or CC. Because the most effec-
tive treatment of CHCC is surgical intervention, early diag-
nosis with developed radiological studies and valuable clin-
ical parameters is very important.
In previous studies of biological behavior and clinico-
pathological features of CHCC, CHCC was not regarded 
simply as a combination of ordinary HCC and ordinary CC. 
Jarnagin, et al.8 reported that CHCC more closely resembled 
CC and that the biliary differentiation component of CHCC 
may contribute to poor prognosis. Ng, et al.13 reported that 
the clinicopathological features of CHCC were similar to 
those of HCC. Other studies8,12 have shown varied preva-
lence of viral hepatitis and underlying cirrhotic liver in the 
CHCC group compared to those in the HCC or CC group. In 
our study, the prevalence of underlying cirrhosis in the liver 
was higher in patients with CHCC than in the HCC and CC 
groups, which indicates that patients with CHCC had less 
well-preserved liver function at the time of operation.
When comparing the characteristics of CHCC to HCC 
and CC, S. Chantajitr, et al.18 and Jarnagin, et al.8 found no 
differences in tumor size, the number of tumors, the pres-
ence of major vascular invasion (portal vein and hepatic vein), 
or the presence of lymph node metastasis between the three 
groups. In contrast, our study showed higher frequencies of 
multifocal tumors and portal vein thrombosis, similar to 
data reported by Koh, et al.1 and Yano, et al.14 In addition, 
an advanced AJCC stage and the presence of intrahepatic 
metastasis were more frequently found among CHCC pa-
tients. Lymph node metastasis of CHCC was comparable 
with that of CC, and significantly higher than that of HCC.
Few have reported on the prognosis of CHCC after surgical 
resection. Most studies have shown that survival of patients 
with CHCC was poorer than that of HCC patients.1,3,8,14,19 In 
Hana Park, et al.
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8. Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, 
et al. Combined hepatocellular and cholangiocarcinoma: demo-
graphic, clinical, and prognostic factors. Cancer 2002;94:2040-6. 
9. Honda H, Onitsuka H, Yasumori K, Hayashi T, Ochiai K, Gibo M, 
et al. Intrahepatic peripheral cholangiocarcinoma: two-phased dy-
namic incremental CT and pathologic correlation. J Comput Assist 
Tomogr 1993;17:397-402. 
10. Honda H, Ochiai K, Adachi E, Yasumori K, Hayashi T, Kawashima 
A, et al. Hepatocellular carcinoma: correlation of CT, angiographic, 
and histopathologic findings. Radiology 1993;189:857-62. 
11. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. 
Combined hepatocellular-cholangiocarcinoma. A histologic and 
immunohistochemical study. Cancer 1985;55:124-35. 
12. Liu CL, Fan ST, Lo CM, Ng IO, Lam CM, Poon RT, et al. Hepatic 
resection for combined hepatocellular and cholangiocarcinoma. 
Arch Surg 2003;138:86-90. 
13. Ng IO, Shek TW, Nicholls J, Ma LT. Combined hepatocellular-
cholangiocarcinoma: a clinicopathological study. J Gastroenterol 
Hepatol 1998;13:34-40. 
14. Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shi-
mada K, et al. Combined hepatocellular and cholangiocarcinoma: 
a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 
2003;33:283-7. 
15. Lin G, Toh CH, Wu RC, Ko SF, Ng SH, Chou WC, et al. Combined 
hepatocellular cholangiocarcinoma: prognostic factors investigated 
by computed tomography/magnetic resonance imaging. Int J Clin 
Pract 2008;62:1199-205.
16. Bhagat V, Javle M, Yu J, Agrawal A, Gibbs JF, Kuvshinoff B, et 
al. Combined hepatocholangiocarcinoma: case-series and review 
of literature. Int J Gastrointest Cancer 2006;37:27-34. 
17. Kim H, Park MS, Park YN, Kim H, Kim KS, Choi JS, et al. Pre-
operative radiologic and postoperative pathologic risk factors for 
early intra-hepatic recurrence in hepatocellular carcinoma patients 
who underwent curative resection. Yonsei Med J 2009;50:789-95. 
18. Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Com-
bined hepatocellular and cholangiocarcinoma: clinical features 
and prognostic study in a Thai population. J Hepatobiliary Pancre-
at Surg 2006;13:537-42. 
19. Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, et al. Com-
parison of combined hepatocellular and cholangiocarcinoma with 
hepatocellular carcinoma and intrahepatic cholangiocarcinoma. 
Surg Today 2006;36:892-7. 
20. Okuda K. Natural history of hepatocellular carcinoma including 
fibrolamellar and hepato-cholangiocarcinoma variants. J Gastro-
enterol Hepatol 2002;17:401-5. 
21. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. 
Combined hepatocellular-cholangiocarcinoma. A histologic and 
immunohistochemical study. Cancer 1985;55:124-35. 
22. Tanaka S, Yamamoto T, Tanaka H, Kodai S, Ogawa M, Ichikawa 
T, et al. Potentiality of combined hepatocellular and intrahepatic 
cholangiocellular carcinoma originating from a hepatic precursor 
cell: Immunohistochemical evidence. Hepatol Res 2005;32:52-7. 
CHCC is low, multicenter studies would be required to in-
vestigate postoperative adjuvant therapy and multimodality 
treatment for CHCC.
In conclusion, most reports have indicated that surgical 
intervention, including resection of lymph nodes, was the 
only effective treatment for CHCC. However, patients with 
CHCC have a significantly poorer survival outcome after 
hepatic resection than do patients with HCC or CC. The 
presence of portal vein thrombosis appears to be useful in 
predicting the prognosis of patients with CHCC, and fur-
ther studies on effective treatment modalities and clinical 
predictors for CHCC are required to prolong the survival of 
these patients.
ACKNOWLEDGEMENTS
This study was supported by grant from the Good Health R 
& D Project of the Ministry of Health and Welfare, Repub-
lic of Korea (A050021).
REFERENCES
1. Koh KC, Lee H, Choi MS, Lee JH, Paik SW, Yoo BC, et al. Clini-
copathologic features and prognosis of combined hepatocellular 
cholangiocarcinoma. Am J Surg 2005;189:120-5. 
2. Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. 
Combined hepatocellular and cholangiocarcinoma: proposed cri-
teria according to cytokeratin expression and analysis of clinico-
pathologic features. Hum Pathol 1995;26:956-64. 
3. Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro 
M. A clinicopathological study on combined hepatocellular and 
cholangiocarcinoma. J Gastroenterol Hepatol 1996;11:758-64. 
4. Gibson JB, Sobin LH. Histological typing of tumours of the liver, 
biliary tract, and pancreas. Geneva: World Health Organization; 
1978. 
5. Ishak KG, Anthony PP, Sobin LH. Histological typing of tumors 
of the liver. 2nd ed. Berlin: Springer; 1994. 
6. ALLEN RA, LISA JR. Combined liver cell and bile duct carcino-
ma. Am J Pathol 1949;25:647-55. 
7. Choi SB, Kim KS, Choi JY, Park SW, Choi JS, Lee WJ, et al. The 
prognosis and survival outcome of intrahepatic cholangiocarcino-
ma following surgical resection: association of lymph node metas-
tasis and lymph node dissection with survival. Ann Surg Oncol 
2009;16:3048-56. 
